Related Experiment Video
Updated: May 28, 2026
11:02
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
Current and emerging strategies in bladder cancer
Simone Carradori1, Cristiano Cristini, Daniela Secci
1Dipartimento di Chimica e Tecnologie del Farmaco and Dipartimento di Scienze Ginecologico- Ostetriche e Scienze Urologiche, Sapienza University of Rome, P.le A. Moro 5, 00185 Rome, Italy. simone.carradori@uniroma1.it
Anti-Cancer Agents in Medicinal Chemistry
|November 3, 2011
Summary
Urothelial cell carcinoma treatments face challenges with response rates and side effects. This review explores novel molecular therapies, including epigenetic modulators and kinase inhibitors, for improved urothelial carcinoma treatment outcomes.
Area of Science:
- Oncology
- Urology
- Molecular Biology
Background:
- Urothelial cell carcinoma (UCC) is a common urinary tract malignancy.
- Standard treatments like intravesical chemo- and immunotherapy have limitations, including side effects and treatment resistance in ~30% of patients.
- Muscle-invasive bladder cancer (MIBC) is aggressive, requiring radical cystectomy, despite modest chemosensitivity.
Purpose of the Study:
- To review promising global or pathway-based therapeutic approaches for urothelial carcinoma.
- To highlight novel agents tested in clinical trials based on a deeper understanding of UCC molecular biology.
- To address the unmet need for effective alternative therapies in bladder cancer.
Main Methods:
- Review of recent clinical trials focusing on molecularly targeted agents for urothelial carcinoma.
- Exploration of various therapeutic strategies including epigenetic modulators, kinase inhibitors, angiogenesis blockers, PPARγ agonists, apoptosis inducers, and virus therapy.
- Synthesis of data on the efficacy and potential of these novel approaches.
Main Results:
- While traditional therapies have limitations, emerging molecularly targeted agents show promise.
- Clinical trials are investigating diverse pathways, including epigenetic modulation and kinase inhibition.
- These novel approaches aim to overcome resistance and improve survival in urothelial carcinoma.
Conclusions:
- Bladder cancer presents significant challenges, necessitating alternative therapeutic strategies.
- Advances in molecular biology support the development of targeted therapies for urothelial carcinoma.
- Promising global and pathway-based approaches are under investigation in clinical trials for improved patient outcomes.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...